CN116801897A - 包含嗜乳脂蛋白的同二聚体和异二聚体蛋白 - Google Patents

包含嗜乳脂蛋白的同二聚体和异二聚体蛋白 Download PDF

Info

Publication number
CN116801897A
CN116801897A CN202180087304.4A CN202180087304A CN116801897A CN 116801897 A CN116801897 A CN 116801897A CN 202180087304 A CN202180087304 A CN 202180087304A CN 116801897 A CN116801897 A CN 116801897A
Authority
CN
China
Prior art keywords
domain
cancer
amino acid
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180087304.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·施赖伯
G·弗罗姆
S·达西瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shattuck Labs Inc
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of CN116801897A publication Critical patent/CN116801897A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180087304.4A 2020-10-26 2021-04-14 包含嗜乳脂蛋白的同二聚体和异二聚体蛋白 Pending CN116801897A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105744P 2020-10-26 2020-10-26
US63/105,744 2020-10-26
PCT/US2021/027294 WO2022093310A1 (en) 2020-10-26 2021-04-14 Homodimeric and heterodimeric proteins comprising butyrophilin

Publications (1)

Publication Number Publication Date
CN116801897A true CN116801897A (zh) 2023-09-22

Family

ID=81384237

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180087304.4A Pending CN116801897A (zh) 2020-10-26 2021-04-14 包含嗜乳脂蛋白的同二聚体和异二聚体蛋白

Country Status (7)

Country Link
US (1) US20230416333A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232065A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023546725A (cg-RX-API-DMAC7.html)
CN (1) CN116801897A (cg-RX-API-DMAC7.html)
AU (1) AU2021370788A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196533A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022093310A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511992A (ja) * 2021-03-16 2024-03-18 シャタック ラボ,インコーポレイテッド ガンマデルタt細胞刺激
WO2023102617A1 (en) * 2021-12-09 2023-06-15 The University Of Melbourne Modified butyrophilin and butyrophilin complexes
WO2024006889A2 (en) * 2022-06-29 2024-01-04 Shattuck Labs, Inc. Cd20-targeted gamma delta t cell modulation
WO2024006907A2 (en) * 2022-06-29 2024-01-04 Shattuck Labs, Inc. B7h3-targeted gamma delta t cell modulation
CN118388647A (zh) * 2022-06-30 2024-07-26 深圳市乐土生物医药有限公司 一种分离的Claudin18.2抗体及其应用
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN121752279A (zh) * 2023-06-30 2026-03-27 科瑞特医药公司 工程化嵌合融合蛋白组合物及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
WO2020146393A1 (en) * 2019-01-07 2020-07-16 Shattuck Labs. Inc. Heterodimeric proteins for modulating gamma delta t cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913573UA (en) * 2015-10-01 2020-03-30 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
WO2020146393A1 (en) * 2019-01-07 2020-07-16 Shattuck Labs. Inc. Heterodimeric proteins for modulating gamma delta t cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOHINDAR M. KARUNAKARAN 等: "Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vγ9Vδ2 TCR and Is Essential for Phosphoantigen Sensing", IMMUNITY, vol. 52, no. 3, 7 March 2020 (2020-03-07) *
刘超英 等: "BTN1A1的研究进展", 饲料研究, no. 24, 23 December 2016 (2016-12-23), pages 16 - 17 *

Also Published As

Publication number Publication date
WO2022093310A1 (en) 2022-05-05
EP4232065A1 (en) 2023-08-30
CA3196533A1 (en) 2022-05-05
AU2021370788A1 (en) 2023-06-22
EP4232065A4 (en) 2024-10-16
JP2023546725A (ja) 2023-11-07
US20230416333A1 (en) 2023-12-28
AU2021370788A9 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
JP7620045B2 (ja) Tigit及びlightベースのキメラタンパク質
JP7303254B2 (ja) I型及びii型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法
US11643447B2 (en) Heterodimeric proteins for modulating gamma delta T cells
US20230416333A1 (en) Homodimeric and heterodimeric proteins comprising butyrophilin
US20240148828A1 (en) Gamma delta t-cell costimulation
RU2775490C2 (ru) Химерные белки на основе tigit и light
HK40091905A (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
HK40092182A (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination